Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires

seekingalpha03-14

Karuna Therapeutics (NASDAQ:KRTX) rose 2.4% in premarket trading after the HSR waiting period for its planned $14 billion sale to Bristol-Myers (NYSE:BMY) expired. The waiting period expired on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2419677257?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg","is_english":true,"pubTime":"2024-03-14 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2419677257","market":"us","top_or_hot":-1,"title":"Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires","media":"seekingalpha","content":"<div>\n<p>Karuna Therapeutics (NASDAQ:KRTX) rose 2.4% in premarket trading after the HSR waiting period for its planned $14 billion sale to Bristol-Myers (NYSE:BMY) expired. The waiting period expired on ...</p>\n\n<a href=\"https://seekingalpha.com/news/4079400-karuna-therapeutics-gains-as-hsr-waiting-period-for-bristol-myers-deal-expires\">Source Link</a>\n\n</div>\n","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaruna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-14 19:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4079400-karuna-therapeutics-gains-as-hsr-waiting-period-for-bristol-myers-deal-expires><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Karuna Therapeutics (NASDAQ:KRTX) rose 2.4% in premarket trading after the HSR waiting period for its planned $14 billion sale to Bristol-Myers (NYSE:BMY) expired. The waiting period expired on ...</p>\n\n<a href=\"https://seekingalpha.com/news/4079400-karuna-therapeutics-gains-as-hsr-waiting-period-for-bristol-myers-deal-expires\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574055.USD","symbol_name":"富达全球健康医疗A ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4079400-karuna-therapeutics-gains-as-hsr-waiting-period-for-bristol-myers-deal-expires","article_id":"2419677257","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2419677257","pubTimestamp":1710416697,"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"Karuna Therapeutics  rose 2.4% in premarket trading after the HSR waiting period for its planned $14 billion sale to Bristol-Myers  expired. The waiting period expired on Wednesday, according to an 8-K filing on Thursday. Bristol-Myers  agreed to acquire neuroscience drug firm Karuna  for $14 billion in cash in December. Bristol Myers  agreed to pay $330 a share for Karuna  and its experimental schizophrenia drug KarXT.  Developing story ...   More on Karuna Therapeutics  Bronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of Process Karuna Therapeutics: Getting Sold Short Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb M&A activity expected to pick up in 2024, bankers say Seeking Alpha’s Quant Rating on Karuna Therapeutics","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0882574055.USD":"富达全球健康医疗A ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4126":"金属与玻璃容器","BK4532":"文艺复兴科技持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4007":"制药","BMY":"施贵宝","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4535":"淡马锡持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4559":"巴菲特持仓","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","KRTX":"Karuna Therapeutics","LU0237698245.USD":"富达环球地产基金A","BK4588":"碎股","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4581":"高盛持仓","MYE":"Myers Industries Inc","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD"},"translate_title":"Karuna Therapeutics获得收益，HSR等待百时美施贵宝交易的时间到期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1,"KRTX":1,"BMY":1},"content_text":"Karuna Therapeutics (NASDAQ:KRTX) rose 2.4% in premarket trading after the HSR waiting period for its planned $14 billion sale to Bristol-Myers (NYSE:BMY) expired. The waiting period expired on Wednesday, according to an 8-K filing on Thursday. Bristol-Myers (BMY) agreed to acquire neuroscience drug firm Karuna (KRTX) for $14 billion in cash in December. Bristol Myers (BMY) agreed to pay $330 a share for Karuna (KRTX) and its experimental schizophrenia drug KarXT.  Developing story ...   More on Karuna Therapeutics  Bronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of Process Karuna Therapeutics: Getting Sold Short Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb M&A activity expected to pick up in 2024, bankers say Seeking Alpha’s Quant Rating on Karuna Therapeutics","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2419677257"}